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Summary. — Prostate Cancer (PCa) is one of the most prevalent cancers world-
wide. Early and accurate diagnosis of PCa is crucial for effective and successful
treatment. Our project aims at developing a unique, highly performing flexible
geometry multi-modality imaging system for diagnosis and staging of PCa. The im-
ager will have the form of an endorectal probe combining high-resolution (0.1 mm)
ultrasound (US) with a very high-resolution Positron Emission Tomography (PET)
probe (1 mm spatial resolution) with exceptional Time-of-Flight (TOF) capability
(100 ps FWHM targeted) compatible with Magnetic Resonance Imaging (MRI), in
coincidence with a set of external PET panels. While standard multiparametric
MRI (mpMR) has drawbacks, diagnosis will be improved significantly by the intro-
duction of PSPMA-PET as well as the simultaneous PET/MR imaging. The system
will be capable of morphological visualization instantly and continuously combined
with biological and metabolic activity, offering crucial improvement with respect to
standard systems (detection of ∼ 2 mm lesions vs. ∼ 6 mm lesions) in spatial resolu-
tion, efficiency, signal-to-noise ratio (SNR), scanning time and/or lowering injected
dose.
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1. – The present status of diagnosis of prostate cancer
Prostate Cancer (PCa) is one of the most prevalent cancers worldwide [1]; early and
accurate diagnosis is crucial for successful treatment. The extent of PCa (prostate, ex-
tracapsular, seminal vesicles) as well as risk stratification as determined by histological
differentiation (Gleason score) of PCa lesions significantly influence further treatment
decisions. Globally, the majority of urology departments still utilize low-resolution US
probes, in conjunction with PSA and Digital Rectal Examination (DRE), to help diag-
nosis and guide biopsy. However it is not very accurate.
Multi-parametrical MR (mpMRI) is increasingly exploited in the diagnosis of PCa and
is becoming the imaging modality of choice for it [1-5]. mpMRI information can then
be used for histological verification of suspicious lesions [4] by means of “fusion biopsy”
(US+mpMRI) [6], recommended by leading urologic guidelines [1]. However mpMRI has
severe drawbacks. The main source of error in MRI leading to false negatives are sparse
and diffuse peripheral tumors [7-10]. Lesions can be overlooked [10]. Both low-grade and
high-grade Gleason score lesions (small, even <1 cm, and large) have serious limitations
in being detected by mpMRI [11,12].
Satellite lesions and peripheral lesions as well as small cancer foci (<0.5 cm3) can
be missed [11, 13, 14]. Moreover large inter-reader variations are accounted for [15].
A study shows that US-mpMRI is not able to detect lesions <3mm [13] that might be
malignant. Positron Emission Tomography (PET) with specific tracers (PSMA) signif-
icantly improved diagnosis of PCa, showing a higher specificity and sensitivity for the
detection of tumor lesions compared to CT, MRI [2, 7, 8, 16]. It showed superior per-
formance also in the identification of metastatic lymph-nodes (LNs) [17] and in biopsy
guidance [18, 19]. Moreover it is a powerful diagnostic tool especially if combined with
mpMR [12]; since mpMR and PET are imaging modalities based on different physical
and biological principles, additional complementary benefit is obtained when they are
combined [2, 7, 8, 16,20,21].
PET and MR have to be simultaneous [22, 23]. The human prostate is flexible and
can be deformed under external conditions, such as patient position or the insertion
of the PET probe, so the localization of the targeted imaging region under the same
circumstances requires using simultaneous MRI and PET. Incorporation of PET/mpMRI
into the workup and monitoring of patients with low-risk prostate cancer can help in
discriminating clinically significant disease from indolent ones [24]; however also this
hybrid method is not perfect and fails to detect microscopic lesions mainly due to the
limited spatial resolution of the standard PET or PET-MR systems (∼3.5mm FWHM):
a very important requirement for a hybrid detector system for diagnosis and staging of
PCa is the capability of detecting very small lesions (∼2–3mm), missed by standard
scanners.
2. – US/TOF–PET/MR proposed system
We propose a unique, innovative, multimodality molecular imaging system that will
merge anatomical and functional details for diagnosis and staging of PCa. The system
integrates, for simultaneous US/TOF–PET/MRI, high-resolution (0.1 mm) ultrasound
(US) and, benefitting from the magnification PET geometry, a very high-resolution/high-
efficiency PET probe in coincidence with very high-resolution/high-efficiency external
PET panels with unprecedented Time-of-Flight (TOF) capability, placed close to the
body of the of the patient [25]. Our target spatial resolution for the system is ∼1mm.
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Fig. 1. – Evaluation of detection capability of small lesion as a function of lesion diameter
and detector spatial resolution. The lesion is modeled by a sphere with uniform activity. The
recovery coefficient (defined as the maximum value of the sphere in the reconstructed image,
divided by the true value of the uniform sphere) is shown as a function of the sphere diameter
for systems with different spatial resolution. For a 3 mm diameter sphere, the image contrast is
increased with a factor of 5 when the system resolution is improved from 4 mm to 2 mm.
The detector system will exactly localize within the prostate even small PCa lesions
missed with standard PET-MR scanners. It also offers the possibility of real-time diag-
nosis of suspicious tracer accumulations within the prostate by directly guiding targeted
biopsies [18]. Adding high-resolution TOF-PET imaging to endoscopy is a real revo-
lution of wide reach, important especially in the case of high background [26]. The
system will be much cheaper and crucially more performant than the whole-body stan-
dard PET/MRI; it will be designed to operate, potentially, inside practically any MRI
scanner with high potential for wide utilization.
Figure 1 shows the recovery coefficient (the ratio of the apparent tracer uptake in the
image to the true tracer uptake) for spheres with different diameter (that mimic different
lesions), as a function of the system resolution. This illustrates the importance of the
system resolution for the detection and correct diagnosis of small lesions. Our proposed
detector system (∼1mm resolution) will enable accurate imaging of spheres as small as
2 mm, whereas with current state of the art PET scanners (3.5 mm resolution), such
spheres will appear as a small fluctuation in the background (fig. 1).
As seen previously it is highly desirable [27] to detect lesions as small as 2 mm not
within reach of the best standard detectors. Better PET performances are needed: spatial
and TOF resolution, efficiency, all of them impacting the Signal-to-Noise Ratio (SNR)
strongly related to the lesion detectability. In this respect, fig. 2 illustrates the impact
of resolution improvements on the amount of information that the PET system acquires
about the difference between a small hot lesion and a larger but far less hot region.
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Fig. 2. – An ideal observer study was done to quantify the amount of information for discrimi-
nating two lesions, provided by PET projections with a particular spatial resolution. Lesion 1
had a 2 mm diameter and tissue-to-background ratio of 5, lesion 2 had a 3.5 mm diameter and
a tissue-to-background ratio of 1.75. The information was quantified as the SNR of the ideal
observer. It is observed that improving the system resolution from 4 mm to 2 mm leads to a 5.3
fold SNR improvement. Discrimination of such lesions is expected to be clinically relevant for
prostate imaging with PSMA-PET.
As is shown in the figure, the SNR of the ideal observer increases with a factor of more
than 5 for the discrimination between a lesion with a tissue-to-background value of 5
(which would be considered very suspicious in PSMA imaging) and a larger lesion with
tissue-to-background ratio of 1.75 (which could be normal or benign uptake).
2.1. The endorectal probe. – The probe and a schematic layout of the system are shown
in fig. 3. The detector system will allow the simultaneous acquisition of PET/MRI im-
ages. We will use LYSO or LSO doped with calcium as scintillator material for the PET
Fig. 3. – (a) Relevant anatomic details. (b) The layout of the PET probe used with dedicated
PET external panels. The PET system uses coincidences between the internal detector (probe)
and the external panels as well as coincidences between the panels [28].
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Fig. 4. – (a) The layout of the endorectal probe. (b) Stabilization of the internal and external
probe temperatures.
detectors. The dimension of the pixelated scintillator is ∼25× 50× 13 mm3. The scintil-
lator pixels (1×1 mm2) will be coupled one to one double side to the SiPM pixels in order
to optimize light collection for spatial and timing resolution and Depth of Interaction
(DOI) [29, 30]. Silicon PhotoMultipliers (SiPM) will be used as photodetectors (Hama-
matsu SiPM S13615-1050N-08, or better ones if they appear on the market). They are
compact, insensitive to magnetic fields and have very good timing properties [31].
The layout of the detection probe is shown in fig. 4(a) [25]. The probe cage is a
cylinder with external diameter of 35 mm. Cool air will be used for the electronics; water
flow in the interstices of the container will allow stabilizing the external temperature
of the probe (fig. 4(b)); we will consider other options like warm air cooling and very
effective insulators [32]. We will choose the most effective and the safest one.
All selected materials will be biocompatible with the human body [33] according to
current regulations and non-magnetic to be compatible with MRI scanners. Shielding
of the RF field to the PET electronics is needed to minimize the effect of eddy cur-
rents. A Korean group did a detailed study of thickness, area and open area of a copper
mesh, as a function of the relative position of PET detector and RF coil on MRI [34].
Cherry’s group found that carbon fiber composite material was a good RF shield at
the Larmor frequency while introducing negligible gradient Eddy currents [35]. More-
over Ziemons and collaborators proposed the separation into two areas but linked via
high-value capacitors [36].
A high-resolution US sensor will be installed in front of the PET probe for position
tracking, to assure high-resolution imaging and accurate guiding [37-39] of biopsy. Opti-
cal and MR tracking systems will be considered in order to know the exact position and
direction of the probe with respect to the PET panels and the prostate [40-43]. We will
choose the best for accuracy and practical reasons.
2.2. External TOF-PET panels. – Angular coverage sufficient to get artefact free
images will be needed for a given TOF resolution; the better the TOF resolution, the
smaller the coverage necessary [44]. We will use (4 + 4) external PET panels on the
opposite sides of the pelvic region of the patient (each panel has an area of ∼100×250×
20 mm3) with scintillator pixels of 2×2 mm2 coupled one to one (double sides to optimize
DOI) to SiPM of the same pitch.
The layout and the pixel size are chosen as the best compromise to obtain excellent
spatial resolution, efficiency and TOF resolution (because of their small capacitance).
The analysis of data from phantom and clinical trial will be analyzed with single- and
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double-side coupling of scintillators with SIPM in order to evaluate the DOI and its
impact on the image quality. The analysis will be performed at full and reduced angular
coverage, e.g., 4 + 4 and less PET panel configuration to know the optimal solution
performance/complexity/cost.
2.3. Time of Flight (TOF). – The time-of-flight information (i.e., arrival time dif-
ference of the detected photons) allows reducing the uncertainty in the localization
of the annihilation place along the line connecting the pixels/crystals fired in coinci-
dence. Time resolution of the best scanner is <250 ps (FWHM) range, translating into
∼3.75 cm (FWHM) positional uncertainty. With 100 ps the positional uncertainly would
be ∼1.5 cm [26,45].
Timing resolution depends on several parameters like scintillator properties (light
output, timing), path length spread (light collection), transit time in the photodetector,
TDC time spread, discriminator time spread, system noise contributions (power supply,
clocks, cables). All of these contributing factors will be optimized: one-on-one coupling
of scintillator pixels with SiPMs, using SiPMs with low capacitance, and a new ASIC.
So a timing resolution of 100 ps will be possible.
For the center of a uniform object which is large compared to the TOF uncertainty,
improving the TOF resolution by a particular factor results in a decrease of noise variance
in the reconstructed image by the same factor. As a result, the SNR increases by the
square root of that factor.
Table I shows the improvement of SNR as a function of the timing resolution. The
excellent TOF resolution will allow us to have PET images almost free from artefact
despite incomplete angular coverage [44] and will facilitate attenuation correction [46].
Preliminary results from our team show that a detector with very good planar and DOI
(<1 mm) resolutions and with good TOF resolution can be realized [25,29,30].
2.4. The new ASIC and electronics to improve TOF resolution. – The proposed sys-
tem requires very compact electronics and a dedicated multi-channel ASIC for fast tim-
ing. SiPM detectors benefit from a large deposited charge and a very short current
pulse (<100 ps) but suffer from large sensor capacitance. To cover large areas with
excellent timing resolution it is therefore necessary to match sensor size and readout
electronics.
The preamplifier need to be optimized in order to obtain the largest bandwidth while
taking into account the connection to the sensor. This will require minimizing the stray
inductance and will be achieved by using a flip chip technique. The chip will comprise 64
channels of innovative preamplifier and high-speed discriminator, coupled to low-power
Table I. – Improvement of SNR and NEC as a function of the timing resolution.
Time resolution (ns) Δx (cm) TOF noise var gain TOF SNR gain
0.1 1.5 26.7 5.2
0.3 4.5 8.9 3.0
0.6 9.0 4.4 2.1
1.2 18.0 2.2 1.5
2.7 40.0 1.0 1.0
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time-to-digital converters; digital processing will allow output the data at high Gb/s
speed.
The new ASIC design will strongly benefit from the experience gained by the group
in developing challenging ASIC for particle physics. Specifically it is proposed to adapt
the preamplifier to SiPM signals exploiting the RF architecture used in PETIROC [47]
and adapt the advanced ALTIROC [48,49] design to the TOF-PET readout. The former
chip, targeted to TOF application, reads 32 SiPM channels with 1 GHz bandwidth that
feature an 18 ps RMS jitter with 4 photoelectron threshold. Internal ADCs and TDCs
provide digitized charge and time information for channels above threshold. The power
dissipation of 200 mW and TFBGA 12 × 12 mm package allow mounting it very close
to the sensors [50]. The latter ALTIROC new-generation 130 nm CMOS chip relies on
advanced high-speed ASIC for 10 ps timing on large areas of LGAD diodes.
2.5. The high-resolution compact US device. – US imaging systems for TRUS work in
the 5–10 MHz with resolutions of several hundred μm. There is a trade-off between reso-
lution and penetration depth in ultrasound, since acoustic damping is strongly frequency-
dependent. MicroUS (μUS) has been lately made available. Lower penetration depths
are required in prostate imaging compared to other organs so higher frequencies pro-
viding better resolution can be used. We will achieve further and significant progress
with μUS devices by introducing high-pitched ultrasound arrays pushing the resolution
limit towards 100 μm. Such arrays will be integrated within very small volumes using
extremely small interconnects to external imaging instrumentation, allowing us to in-
tegrate it in the PET probe. The μUS devices will be optimized to allow penetration
through the full depth of the prostate with the best possible spatial resolution, providing,
potentially, also additional diagnostic information. Shear wave elastography which gives
access to the tissue stiffness that has been demonstrated to be an indicator for tissue
malignancy [37-39] will be supported.
2.6. PET/MRI compatibility . – It has been shown that both modalities preserve
their functionality, even when operated isochronously [51]. The average MR image SNR
showed small degradations when the PET insert was put in the magnet [52]. We per-
formed measurements with our prototype of the prostate probe in a 4.7 T scanner [25].
Test results showed that overall the PET device does not cause a significant loss of the
MR signal to noise and therefore would not prevent the simultaneous use of both the
MRI coil and the PET device within a clinical scanner [25].
2.7. Endorectal MR coil . – MR imaging with endorectal coil (ERC) in local staging of
prostate cancer is debated extensively in the literature [50]. It is undisputed that SNR
and spatial resolution are significantly better by the use of an ERC imaging technol-
ogy than a standard pelvic phase array coil [53]. Moreover, a number of studies have
demonstrated improvements in the detection quality and localization accuracy using the
endorectal type of coils relative to other methods [53-55].
Despite the clear advantages of using hybrid MR-PET systems, there are technical
challenges to be taken into account. For example the efficiency of the RF coil could be
affected from the needed shielding of the PET probe; some effect could be induced on
the MR image. However it has been shown by Choi and Ziemons that with a careful
choice of the coil both the MR and PET images are excellent [36]. Based on this result,
we will exploit this knowledge to design and build an ERC detector system as indicated
in [36].
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2.8. Reconstruction software. – Development of dedicated high-resolution PET image
reconstruction software for accurate and precise images of the prostate is a challenging
objective that will require novel TOF reconstruction algorithms for the proposed PET
detection system (flexible geometry with limited angular coverage). This software will
use the available probe position information, provided by the passive tracking arm, to
calibrate the particular PET system geometry that changes with the changing position
of the endorectal probe. It will include correction for photon attenuation and Comp-
ton scatter [40, 41] either based on the MR-based attenuation map (MRAC) or, if the
PET system is operated outside the MR, using attenuation estimates obtained from the
TOF-PET data themselves [56, 57]. In addition, based on the geometry, and, if neces-
sary, on joint estimation techniques applied to the TOF-PET data, it will estimate the
detector-pair sensitivities [46,58-61]. Due to these corrections, images of good visual and
quantitative quality will be obtained.
3. – Preclinical tests and plot clinical trials
Once all the above components have been integrated into a demonstrator system, it
will undergo extensive preclinical tests before final clinical trials.
In the first step we will use solid positron emitting point sources placed within a
gel matrix and the detection capability of these sources by the PET component of the
developed prototype will be evaluated. For phantom evaluation a multi-modality prostate
training phantom will be prepared to contain inserts of 68Ga or 18F or other positron
emitters. After imaging using a standard PET/MR scanner the phantom will be imaged
by the developed system with position tracking to generate a 3D-image volume.
The validity of the new system data will be evaluated by a comparison with PET/MR
images. In the third step the biopsy guidance fixture will be attached to the developed
endorectal probe system and bioptic puncture of the radioactive lesions will be performed.
Image reconstruction and fusion as well as needle tracking will be fully operational during
these tests.
The accuracy of the novel system will be then assessed in a pilot clinical trial. A total
of 50 patients with clinically localized prostate cancer undergoing radical prostatectomy
will be identified. All patients will subsequently undergo a study with the Signa PET/MR
scanner with phase array coil. All patients will be preoperatively evaluated using the
novel system with endorectal and phase array coils at least 6 weeks after prostate biopsy.
Fusion biopsy will be performed adding the PET probe images to the mpMRI ones. Then
all patients will be treated with a robot-assisted radical prostatectomy with or without
lymph-node dissection according to disease characteristics. All resected specimens will
be analyzed by expert high-volume uro-pathologists.
The primary endpoint will be represented by the detection of clinically significant
prostate cancer, defined as the presence of lesions with Gleason score ≥3 + 4 at final
pathology. Secondary endpoints will be the detection of extracapsular extension and/or
seminal vesicle invasion. The performance characteristics of the novel imaging method for
the detection of clinically significant prostate cancer and for local staging will be assessed
and compared with mpMRI and PET/mpMRI. The pathologic report will represent the
gold standard.
The performance of the novel imaging system will be assessed for different outcomes
in the overall population and after stratifying patients according to preoperative PSA
values and Gleason score. The receiver operating characteristics area under the curve
method will estimate the predictive accuracy of these methods.
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4. – Conclusions and outlook
Our ambitious project main goal is the development of the high-resolution dedicated
prostatic US/TOF-PET system, compatible with MRI, in order to improve:
• Lesion detectability through better signal-to-noise ratio (obtained also by dramatic
suppression of partial volume effects) in detecting and discriminating small lesions
with much higher spatial resolution PET system.
• Angular coverage needed to obtain (almost) artifact-free PET images and high
sensitivity, and in consequence short scanning time, and/or low dose.
• Accuracy by which the attenuation correction can be estimated from TOF-PET
data.
Such a complex system needs the careful evaluation of different configurations for opti-
mization of performances, complexity, cost, within acceptable clinical requirements. The
final demonstrator prototype will be used for preclinical tests to evaluate and validate
its performance on phantoms, and then in clinical trials.
REFERENCES
[1] Mottet Nicolas et al., Eur. Urol., 71 (2017) 618.
[2] Yilmaz B. et al., The Prostate, 79 (2019) 1007.
[3] Torre L. A. et al., CA Canc. J. Clin., 65 (2015) 87.
[4] Ahmed H. U. et al., Lancet, 389 (2017) 815.
[5] Margolis D. J. A. et al., BioMed. Res. Int., 2014 (2014) 684127.
[6] Valerio M et al., Eur. Urol., 68 (2015) 8.
[7] Perera M. et al., Eur. Urol., 70 (2016) 926.
[8] Abd Alkhalik Basha Mohammad et al., Abdom. Radiol., 44 (2019) 2545.
[9] Dianat S. S. et al., Urol. Oncol., 32 (2014) e1.
[10] Taneja S. et al., Am. J. Roentgenol., 210 (2018) 1338.
[11] Le J. D. et al., Eur. Urol., 67 (2015) 569.
[12] Rahbar K. et al., J. Nucl. Med., 57 (2016) 563.
[13] Rastinehad A. R. et al., J. Urol., 185 (2011) 815.
[14] Schouten M. G. et al., Eur. Urol., 71 (2017) 896.
[15] Sonn G. A., Eur. Urol. Focus, 5 (2019) 592.
[16] Hicks R. M. et al., Radiology, 289 (2018) 730.
[17] Jilg C. A. et al., Theranostics, 7 (2017) 1770.
[18] Maurer T. et al., Nat. Rev. Urol., 13 (2016) 226.
[19] Eiber M. et al., Eur. Urol., 70 (2016) 829.
[20] Westenfelder K. M. et al., Clin. Genitourinary Canc., 16 (2018) 245.
[21] Mottaghy F. M. et al., Eur. J. Nucl. Med. Mol. Imaging, 43 (2016) 1397.
[22] Bailey D. L. et al., Mol. Imaging Biol., 20 (2018) 4Y20.
[23] Herzog Hans Z., Med. Phys., 22 (2012) 281.
[24] Dianat S. S. et al., Urol. Oncol.: Sem. Orig. Inv., 32 (2014) 39.
[25] Garibaldi F. et al., Eur. Phys. J. Plus, 132 (2017) 396.
[26] Moses W. W., Nucl. Instrum. Methods A, 580 (2007) 919.
[27] Tan Nelly et al., Am. J. Roentgenol., 205 (2015) W87.
[28] von Eyben F. E. et al., Eur. Urol. Focus., 4 (2016) 686.
[29] Cosentino L. et al., Rev. Sci. Instrum., 83 (2012) 114301.
[30] Cosentino L. et al., Rev. Sci. Instrum., 83 (2012) 84302.
[31] Renker D., Nucl. Instrum. Methods A, 567 (2006) 48.
10 F. GARIBALDI et al.
[32] https://m.indiamart.com/proddetail/super-multilayer-insulation-pads-90884121
33.html.
[33] Gagan Kaur et al., RSC Adv., 5 (2015) 37553 and https://www.quadrantplastics.
com/eu-en/industries/medical-life-science.html.
[34] Kang Jihoon et al., 2009 IEEE Nuclear Science Symposium Conference Record M13-261
(IEEE) 2009, https://doi.org/10.1109/NSSMIC.2009.5401902.
[35] Peng Bo J. et al., J. Magn. Reson., 239 (2014) 50.
[36] Choi C.-H. et al., Design, evaluation and comparison of RF surface coils for hybrid MR-
PET imaging of the prostate, to be published in Phys. Med. Biol.
[37] Rohrbach D. et al., Ultrasound Med. Biol., 44 (2018) 1341.
[38] Pavlovich C. et al., Urol. Oncol., 32 (2014) 34.e27.
[39] Wei C. et al., J. Urol., 200 (2018) 549.
[40] Maier-Hein L. et al., Proc. SPIE, 6918 (2008) 1605.
[41] Elfring Robert et al., Comput. Aided Surg., 15 (2010) 1.
[42] Eschelbach Martin et al., Proc. Intl. Soc. Mag. Reson. Med., 25 (2017) 1304.
[43] Godenschweger F. et al., Phys. Med. Biol., 61 (2016) R32.
[44] Surti S. et al., Phys. Med. Biol., 53 (2008) 2911.
[45] Lecoq P., these Proceedings.
[46] Defrise M. et al., Phys. Med. Biol., 57 (2012) 885.
[47] Monzo J. M. et al., J. Instrum., 12 (2017) C02059.
[48] De La Taille C. et al., PoS TWEPP-17 (2018) 006 AIDA-2020-CONF-2018-005 and
CERN-LHCC-2018-023; LHCC-P-012.
[49] Omega-Centre de Microelectronic-Product Specs Web Site, https://portail.poly
technique.edu/omega/en/products/products-presentation.
[50] Dickinson L. et al., J. Magn. Reson. Imaging, 36 (2013) 48.
[51] Judenhofer M. et al., Nat. Med., 14 (2008) 439.
[52] Berneking A. et al., IEEE Trans. Nucl. Sci., 64 (2017) 1118.
[53] Costa D. N. et al., Urol. Oncol.: Sem. Orig. Inv., 34 (2016) 255.e7.
[54] Gawlitza J. et al., Sci. Rep., 7 (2017) 40640.
[55] Sosna J. et al., Acad. Radiol., 11 (2004) 857.
[56] Rezaei A. et al., IEEE Trans. Med. Imaging, 33 (2014) 1563.
[57] Defrise M. et al., Phys. Med. Biol., 59 (2014) 1073.
[58] Mehranian A. and Zaidi H., IEEE Trans. Med. Imaging, 34 (2015) 1808.
[59] Rezaei A. et al., IEEE Trans. Med. Imaging, 31 (2012) 2224.
[60] Rezaei A. et al., IEEE Trans. Med. Imaging, 39 (2020) 952.
[61] Rezaei A. et al., Maximum Likelihood Estimation of the Geometric Sensitivities, in PET
2019 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC)
(IEEE) 2019.
